Unidad de Epidemiología del VIH/SIDA, Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain.
BMC Infect Dis. 2010 Sep 14;10:267. doi: 10.1186/1471-2334-10-267.
Previous studies have demonstrated the efficacy of treatment for latent tuberculosis infection (TLTBI) in persons infected with the human immunodeficiency virus, but few studies have investigated the operational aspects of implementing TLTBI in the co-infected population.The study objectives were to describe eligibility for TLTBI as well as treatment prescription, initiation and completion in an HIV-infected Spanish cohort and to investigate factors associated with treatment completion.
Subjects were prospectively identified between 2000 and 2003 at ten HIV hospital-based clinics in Spain. Data were obtained from clinical records. Associations were measured using the odds ratio (OR) and its 95% confidence interval (95% CI).
A total of 1242 subjects were recruited and 846 (68.1%) were evaluated for TLTBI. Of these, 181 (21.4%) were eligible for TLTBI either because they were tuberculin skin test (TST) positive (121) or because their TST was negative/unknown but they were known contacts of a TB case or had impaired immunity (60). Of the patients eligible for TLTBI, 122 (67.4%) initiated TLTBI: 99 (81.1%) were treated with isoniazid for 6, 9 or 12 months; and 23 (18.9%) with short-course regimens including rifampin plus isoniazid and/or pyrazinamide. In total, 70 patients (57.4%) completed treatment, 39 (32.0%) defaulted, 7 (5.7%) interrupted treatment due to adverse effects, 2 developed TB, 2 died, and 2 moved away. Treatment completion was associated with having acquired HIV infection through heterosexual sex as compared to intravenous drug use (OR:4.6; 95% CI:1.4-14.7) and with having taken rifampin and pyrazinamide for 2 months as compared to isoniazid for 9 months (OR:8.3; 95% CI:2.7-24.9).
A minority of HIV-infected patients eligible for TLTBI actually starts and completes a course of treatment. Obstacles to successful implementation of this intervention need to be addressed.
先前的研究已经证明了治疗潜伏性结核感染(LTBI)在感染人类免疫缺陷病毒(HIV)的个体中的疗效,但很少有研究调查在合并感染人群中实施 LTBI 的操作方面。本研究的目的是描述西班牙 HIV 感染队列中 LTBI 的资格以及治疗方案、起始和完成情况,并探讨与治疗完成相关的因素。
2000 年至 2003 年,在西班牙的 10 家 HIV 医院诊所前瞻性地确定了研究对象。从临床记录中获得数据。使用比值比(OR)及其 95%置信区间(95%CI)来衡量关联。
共纳入 1242 名研究对象,其中 846 名(68.1%)接受 LTBI 评估。其中,181 名(21.4%)符合 LTBI 条件,要么是因为他们的结核菌素皮肤试验(TST)阳性(121 名),要么是因为他们的 TST 阴性/未知,但他们是结核病病例的已知接触者或免疫受损(60 名)。在符合 LTBI 条件的患者中,有 122 名(67.4%)开始 LTBI 治疗:99 名(81.1%)接受异烟肼治疗 6、9 或 12 个月;23 名(18.9%)接受包括利福平加异烟肼和/或吡嗪酰胺的短程方案。共有 70 名患者(57.4%)完成治疗,39 名(32.0%)失访,7 名(5.7%)因不良反应中断治疗,2 名发展为结核病,2 名死亡,2 名转移。与静脉吸毒相比,通过异性性行为获得 HIV 感染与完成治疗的可能性更高(OR:4.6;95%CI:1.4-14.7),与接受利福平加吡嗪酰胺治疗 2 个月相比,接受异烟肼治疗 9 个月与完成治疗的可能性更高(OR:8.3;95%CI:2.7-24.9)。
符合 LTBI 条件并实际开始并完成疗程的 HIV 感染患者人数较少。需要解决成功实施这一干预措施的障碍。